 Nichole Carlson
Concepts (522)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 3 | 2025 | 77 | 1.540 |
Why?
| | Bayes Theorem | 6 | 2020 | 368 | 1.270 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 178 | 1.100 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2521 | 1.060 |
Why?
| | Models, Statistical | 6 | 2020 | 625 | 1.020 |
Why?
| | Sarcoidosis | 2 | 2025 | 154 | 0.980 |
Why?
| | Hydrocortisone | 6 | 2015 | 301 | 0.920 |
Why?
| | Outpatients | 7 | 2024 | 366 | 0.880 |
Why?
| | Hormones | 3 | 2017 | 140 | 0.840 |
Why?
| | Emphysema | 1 | 2023 | 95 | 0.800 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 176 | 0.750 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 244 | 0.710 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 732 | 0.690 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 335 | 0.690 |
Why?
| | Diabetes Complications | 1 | 2022 | 224 | 0.680 |
Why?
| | Radiography, Thoracic | 2 | 2024 | 163 | 0.660 |
Why?
| | Disease Susceptibility | 1 | 2021 | 334 | 0.620 |
Why?
| | Metadata | 1 | 2018 | 8 | 0.620 |
Why?
| | Computer Simulation | 4 | 2017 | 939 | 0.580 |
Why?
| | State Health Plans | 2 | 2008 | 32 | 0.580 |
Why?
| | Models, Biological | 3 | 2017 | 1693 | 0.560 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 239 | 0.550 |
Why?
| | Ovary | 3 | 2017 | 214 | 0.550 |
Why?
| | Genome | 1 | 2018 | 277 | 0.520 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 132 | 0.520 |
Why?
| | Reproduction | 1 | 2017 | 201 | 0.510 |
Why?
| | Residence Characteristics | 6 | 2010 | 324 | 0.500 |
Why?
| | Child Health Services | 2 | 2008 | 185 | 0.490 |
Why?
| | Humans | 93 | 2025 | 128524 | 0.470 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 17 | 0.470 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 564 | 0.470 |
Why?
| | Software | 2 | 2019 | 610 | 0.460 |
Why?
| | Brain Injuries | 5 | 2010 | 468 | 0.460 |
Why?
| | Health Services for the Aged | 2 | 2019 | 72 | 0.460 |
Why?
| | Biometry | 2 | 2017 | 69 | 0.450 |
Why?
| | Obesity | 12 | 2023 | 2860 | 0.450 |
Why?
| | Computational Biology | 1 | 2018 | 597 | 0.450 |
Why?
| | Female | 72 | 2025 | 68127 | 0.440 |
Why?
| | Circadian Rhythm | 4 | 2013 | 405 | 0.440 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 28 | 0.430 |
Why?
| | Adult | 52 | 2024 | 35315 | 0.420 |
Why?
| | Pulsatile Flow | 1 | 2013 | 59 | 0.420 |
Why?
| | Environment Design | 3 | 2010 | 26 | 0.420 |
Why?
| | Antibodies, Viral | 5 | 2024 | 593 | 0.420 |
Why?
| | Health Services Accessibility | 4 | 2010 | 892 | 0.410 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 51 | 0.410 |
Why?
| | Aged | 27 | 2024 | 21971 | 0.390 |
Why?
| | Specimen Handling | 1 | 2013 | 165 | 0.380 |
Why?
| | Middle Aged | 37 | 2025 | 30893 | 0.380 |
Why?
| | Saliva | 1 | 2013 | 205 | 0.370 |
Why?
| | Gonadotropins | 3 | 2023 | 37 | 0.370 |
Why?
| | Alzheimer Disease | 4 | 2023 | 515 | 0.350 |
Why?
| | Walking | 4 | 2010 | 494 | 0.350 |
Why?
| | Male | 44 | 2025 | 62883 | 0.350 |
Why?
| | White Matter | 2 | 2023 | 132 | 0.340 |
Why?
| | Lung | 5 | 2025 | 3741 | 0.340 |
Why?
| | Hypogonadism | 2 | 2015 | 82 | 0.330 |
Why?
| | Oregon | 8 | 2011 | 68 | 0.330 |
Why?
| | Levodopa | 2 | 2007 | 29 | 0.330 |
Why?
| | Hospitalization | 8 | 2024 | 2071 | 0.330 |
Why?
| | Activities of Daily Living | 3 | 2010 | 388 | 0.330 |
Why?
| | Parkinson Disease | 4 | 2009 | 451 | 0.330 |
Why?
| | Endocrine System | 1 | 2009 | 20 | 0.320 |
Why?
| | Testosterone | 2 | 2010 | 378 | 0.310 |
Why?
| | Technology | 1 | 2009 | 84 | 0.300 |
Why?
| | Prenatal Care | 1 | 2010 | 271 | 0.300 |
Why?
| | Estradiol | 6 | 2023 | 497 | 0.290 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 48 | 0.290 |
Why?
| | Levonorgestrel | 4 | 2011 | 37 | 0.280 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2430 | 0.280 |
Why?
| | Health Behavior | 3 | 2010 | 740 | 0.280 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.280 |
Why?
| | Cognition Disorders | 3 | 2008 | 496 | 0.280 |
Why?
| | Perception | 2 | 2007 | 337 | 0.280 |
Why?
| | Young Adult | 15 | 2024 | 12320 | 0.270 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1355 | 0.270 |
Why?
| | Methylphenidate | 1 | 2007 | 37 | 0.270 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 55 | 0.270 |
Why?
| | Smoking Cessation | 1 | 2010 | 408 | 0.260 |
Why?
| | Aged, 80 and over | 11 | 2021 | 7040 | 0.260 |
Why?
| | Time Factors | 13 | 2017 | 6503 | 0.250 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2697 | 0.240 |
Why?
| | Poverty | 2 | 2010 | 494 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3618 | 0.240 |
Why?
| | Cluster Analysis | 2 | 2023 | 478 | 0.240 |
Why?
| | Gliosis | 2 | 2023 | 27 | 0.230 |
Why?
| | Healthcare Disparities | 1 | 2010 | 576 | 0.230 |
Why?
| | Health Care Rationing | 1 | 2024 | 58 | 0.220 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 62 | 0.220 |
Why?
| | Denmark | 2 | 2021 | 44 | 0.220 |
Why?
| | Alanine | 1 | 2024 | 141 | 0.220 |
Why?
| | Medicaid | 1 | 2008 | 437 | 0.220 |
Why?
| | Retrospective Studies | 13 | 2024 | 14460 | 0.210 |
Why?
| | Spirometry | 2 | 2024 | 248 | 0.210 |
Why?
| | Risk Factors | 10 | 2022 | 9727 | 0.210 |
Why?
| | Oocytes | 2 | 2020 | 175 | 0.200 |
Why?
| | Body Mass Index | 6 | 2019 | 2262 | 0.200 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1197 | 0.200 |
Why?
| | Benchmarking | 1 | 2023 | 176 | 0.190 |
Why?
| | Aging | 4 | 2008 | 1770 | 0.190 |
Why?
| | Prospective Studies | 9 | 2023 | 7043 | 0.190 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5040 | 0.190 |
Why?
| | Monte Carlo Method | 3 | 2017 | 138 | 0.190 |
Why?
| | Markov Chains | 3 | 2017 | 116 | 0.190 |
Why?
| | Respiratory Function Tests | 2 | 2024 | 582 | 0.190 |
Why?
| | Antiviral Agents | 2 | 2024 | 704 | 0.190 |
Why?
| | Disability Evaluation | 4 | 2018 | 289 | 0.180 |
Why?
| | Doxycycline | 2 | 2011 | 55 | 0.180 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 17 | 0.180 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 92 | 0.180 |
Why?
| | Healthy Aging | 1 | 2021 | 33 | 0.180 |
Why?
| | Weight Gain | 2 | 2022 | 505 | 0.180 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 5 | 0.180 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 93 | 0.180 |
Why?
| | Memory, Episodic | 1 | 2021 | 43 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2022 | 116 | 0.170 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 35 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 187 | 0.170 |
Why?
| | Apomorphine | 3 | 2009 | 5 | 0.170 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 52 | 0.170 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.170 |
Why?
| | Menstruation | 2 | 1991 | 44 | 0.170 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 21 | 0.160 |
Why?
| | Internet | 2 | 2018 | 618 | 0.160 |
Why?
| | Radial Nerve | 1 | 1999 | 9 | 0.160 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 24 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 432 | 0.160 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2736 | 0.160 |
Why?
| | Human Growth Hormone | 2 | 2014 | 44 | 0.160 |
Why?
| | Health Status | 3 | 2010 | 751 | 0.160 |
Why?
| | Astrocytes | 1 | 2021 | 189 | 0.160 |
Why?
| | Cohort Studies | 6 | 2024 | 5369 | 0.160 |
Why?
| | Quality of Life | 5 | 2018 | 2680 | 0.160 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1208 | 0.150 |
Why?
| | Hip Fractures | 1 | 2019 | 82 | 0.150 |
Why?
| | Vital Capacity | 1 | 2019 | 289 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2018 | 110 | 0.150 |
Why?
| | Bibliometrics | 1 | 2018 | 54 | 0.150 |
Why?
| | Case-Control Studies | 5 | 2021 | 3326 | 0.150 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.150 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.150 |
Why?
| | Contraception | 2 | 1991 | 151 | 0.140 |
Why?
| | Adolescent | 14 | 2024 | 20213 | 0.140 |
Why?
| | Eligibility Determination | 2 | 2008 | 63 | 0.140 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.140 |
Why?
| | Algorithms | 3 | 2017 | 1616 | 0.140 |
Why?
| | Rhinitis | 2 | 2010 | 148 | 0.140 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 681 | 0.140 |
Why?
| | Medically Uninsured | 2 | 2008 | 127 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2018 | 106 | 0.140 |
Why?
| | Premature Birth | 1 | 2020 | 311 | 0.140 |
Why?
| | Lactation | 1 | 2018 | 170 | 0.130 |
Why?
| | Psychomotor Performance | 3 | 2009 | 311 | 0.130 |
Why?
| | Family Planning Services | 2 | 2008 | 87 | 0.130 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 98 | 0.130 |
Why?
| | Pregnancy | 8 | 2023 | 6297 | 0.130 |
Why?
| | Hypothyroidism | 2 | 2007 | 71 | 0.130 |
Why?
| | Endoscopy | 2 | 2010 | 267 | 0.130 |
Why?
| | Double-Blind Method | 7 | 2011 | 1860 | 0.130 |
Why?
| | Affect | 3 | 2008 | 285 | 0.130 |
Why?
| | Sinusitis | 2 | 2010 | 202 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 391 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2017 | 3023 | 0.130 |
Why?
| | Low Back Pain | 1 | 2018 | 104 | 0.130 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 169 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2018 | 339 | 0.130 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 255 | 0.130 |
Why?
| | Dietary Fats | 1 | 2018 | 301 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 339 | 0.130 |
Why?
| | Models, Animal | 1 | 2017 | 367 | 0.130 |
Why?
| | Personnel Selection | 1 | 2016 | 73 | 0.120 |
Why?
| | Recovery of Function | 2 | 2010 | 643 | 0.120 |
Why?
| | Otolaryngology | 1 | 2016 | 84 | 0.120 |
Why?
| | Brain | 5 | 2023 | 2618 | 0.120 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.120 |
Why?
| | Cross-Over Studies | 5 | 2009 | 513 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 208 | 0.120 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 143 | 0.120 |
Why?
| | Acromegaly | 1 | 2014 | 12 | 0.120 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.120 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 127 | 0.120 |
Why?
| | Menstrual Cycle | 3 | 2011 | 124 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2017 | 304 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 137 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 421 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 207 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1271 | 0.110 |
Why?
| | Dementia | 2 | 2008 | 227 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 206 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 395 | 0.110 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 757 | 0.110 |
Why?
| | Biomarkers | 4 | 2021 | 3881 | 0.110 |
Why?
| | Antibody Formation | 2 | 2022 | 287 | 0.110 |
Why?
| | Secretory Rate | 1 | 2013 | 18 | 0.110 |
Why?
| | Health Policy | 2 | 2024 | 353 | 0.100 |
Why?
| | Interviews as Topic | 3 | 2010 | 705 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1108 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 168 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 73 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 317 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 206 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1487 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 436 | 0.100 |
Why?
| | Medical Records | 1 | 2013 | 169 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 214 | 0.100 |
Why?
| | Treatment Outcome | 8 | 2024 | 10163 | 0.100 |
Why?
| | Age Factors | 8 | 2018 | 3117 | 0.100 |
Why?
| | Wakefulness | 1 | 2013 | 114 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 386 | 0.100 |
Why?
| | Urban Health | 2 | 2009 | 79 | 0.100 |
Why?
| | Memory | 3 | 2008 | 231 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 525 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4898 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 529 | 0.090 |
Why?
| | Statistics as Topic | 2 | 2009 | 304 | 0.090 |
Why?
| | Cognition | 3 | 2008 | 1107 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 78 | 0.090 |
Why?
| | Insulin | 1 | 2022 | 2318 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 518 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 28 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 39 | 0.090 |
Why?
| | Risk Assessment | 2 | 2017 | 3256 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 30 | 0.090 |
Why?
| | Birth Certificates | 1 | 2010 | 9 | 0.090 |
Why?
| | Estrone | 1 | 2010 | 37 | 0.090 |
Why?
| | Birth Rate | 2 | 2020 | 25 | 0.090 |
Why?
| | Cytokines | 2 | 2015 | 1985 | 0.090 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 39 | 0.090 |
Why?
| | Automobile Driving | 2 | 2010 | 141 | 0.090 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 15 | 0.090 |
Why?
| | Live Birth | 2 | 2020 | 55 | 0.090 |
Why?
| | Pregnancy Rate | 2 | 2020 | 60 | 0.090 |
Why?
| | Geographic Information Systems | 2 | 2010 | 40 | 0.090 |
Why?
| | Diet | 1 | 2018 | 1200 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2017 | 1014 | 0.090 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 76 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 62 | 0.080 |
Why?
| | Cities | 1 | 2010 | 104 | 0.080 |
Why?
| | Registries | 1 | 2017 | 1878 | 0.080 |
Why?
| | United States | 6 | 2020 | 13876 | 0.080 |
Why?
| | Personality | 1 | 2011 | 122 | 0.080 |
Why?
| | Abortion, Induced | 2 | 2008 | 98 | 0.080 |
Why?
| | Sex Factors | 5 | 2018 | 1949 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 8 | 0.080 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 37 | 0.080 |
Why?
| | Telecommunications | 1 | 2009 | 20 | 0.080 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 72 | 0.080 |
Why?
| | Independent Living | 1 | 2010 | 97 | 0.080 |
Why?
| | Mortality | 1 | 2011 | 307 | 0.080 |
Why?
| | Rural Health | 1 | 2009 | 70 | 0.080 |
Why?
| | Progesterone | 3 | 2015 | 244 | 0.080 |
Why?
| | Drug Interactions | 2 | 2007 | 360 | 0.080 |
Why?
| | Postmenopause | 1 | 2010 | 370 | 0.080 |
Why?
| | Exercise | 3 | 2010 | 1937 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 1975 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 10373 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 10 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 84 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 25 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 22 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 12 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 22 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 148 | 0.070 |
Why?
| | Foot | 1 | 2009 | 123 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 43 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 45 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 265 | 0.070 |
Why?
| | Population Surveillance | 1 | 2010 | 427 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 36 | 0.070 |
Why?
| | Disease Progression | 3 | 2015 | 2603 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 386 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 172 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 120 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 15 | 0.070 |
Why?
| | Time Perception | 1 | 2007 | 28 | 0.070 |
Why?
| | Awareness | 1 | 2007 | 99 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 136 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2007 | 174 | 0.070 |
Why?
| | Movement | 1 | 2009 | 267 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 101 | 0.070 |
Why?
| | Tremor | 1 | 2007 | 57 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 1054 | 0.070 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 217 | 0.070 |
Why?
| | Suicide, Attempted | 1 | 2009 | 352 | 0.070 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 129 | 0.060 |
Why?
| | Infant | 3 | 2010 | 8913 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1968 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 581 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 10 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 342 | 0.060 |
Why?
| | Animals | 6 | 2023 | 34501 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 430 | 0.060 |
Why?
| | Administration, Oral | 1 | 2007 | 757 | 0.060 |
Why?
| | Neurologic Examination | 2 | 2008 | 114 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1820 | 0.060 |
Why?
| | Health Promotion | 1 | 2010 | 717 | 0.060 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 73 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2008 | 477 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 562 | 0.060 |
Why?
| | Likelihood Functions | 2 | 2017 | 136 | 0.050 |
Why?
| | Child | 5 | 2018 | 20721 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2024 | 967 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4392 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 11 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 198 | 0.050 |
Why?
| | Family | 1 | 2008 | 642 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 46 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 816 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 73 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 95 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 667 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 727 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 533 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 203 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 393 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 72 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 12 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 820 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1266 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 235 | 0.050 |
Why?
| | Acids | 1 | 2002 | 16 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 123 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1022 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3366 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 63 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1667 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 764 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 151 | 0.050 |
Why?
| | Neuroimaging | 1 | 2023 | 275 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 168 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 143 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 218 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 111 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 15 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 192 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 268 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 47 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 263 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 33 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2139 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 84 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 123 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 1943 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1336 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 216 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1289 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1271 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 98 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 87 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1936 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 837 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 347 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2000 | 355 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.040 |
Why?
| | Milk | 1 | 2018 | 120 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 427 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 318 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 99 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 16 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2619 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 380 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 131 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 62 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 109 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 238 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1265 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 856 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 492 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 323 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2465 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 814 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 770 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 232 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 197 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 61 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1416 | 0.030 |
Why?
| | Systole | 1 | 2015 | 191 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 106 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1190 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 250 | 0.030 |
Why?
| | Risk | 1 | 2017 | 852 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 512 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 903 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 591 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 209 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 106 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 179 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 681 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 656 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3943 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3050 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 374 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5257 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 857 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2008 | 1003 | 0.030 |
Why?
| | Fatty Acids | 1 | 2015 | 413 | 0.030 |
Why?
| | Follicular Phase | 2 | 2004 | 40 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 354 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 617 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 295 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 728 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 551 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1494 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3780 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 22 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 106 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 57 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 60 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5687 | 0.020 |
Why?
| | Amides | 1 | 2010 | 91 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 533 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 170 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 710 | 0.020 |
Why?
| | Income | 1 | 2010 | 189 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 160 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 780 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1046 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 374 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 17 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 102 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 10 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 173 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 35 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 35 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 175 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 14 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 269 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 16 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 827 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 59 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 450 | 0.020 |
Why?
| | Employment | 1 | 2010 | 167 | 0.020 |
Why?
| | Parity | 1 | 1988 | 120 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 8 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 20 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 28 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 25 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 199 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 69 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 391 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 41 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 144 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 88 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 150 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 65 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 470 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 156 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 43 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 480 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 44 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 5346 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 78 | 0.020 |
Why?
| | Research | 1 | 2010 | 409 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 432 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 54 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 240 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 94 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 152 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 89 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 493 | 0.020 |
Why?
| | Safety | 1 | 2008 | 329 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 90 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 644 | 0.020 |
Why?
| | Mental Recall | 1 | 2007 | 184 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 523 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 316 | 0.020 |
Why?
| | Dopamine Agents | 1 | 2005 | 16 | 0.020 |
Why?
| | Virus Diseases | 1 | 2007 | 204 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 629 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 25 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1540 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 460 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 68 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 80 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 44 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 369 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 256 | 0.010 |
Why?
| | Length of Stay | 1 | 2009 | 1121 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 78 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1701 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1038 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 58 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 525 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 318 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 168 | 0.010 |
Why?
| | Skin | 1 | 2007 | 717 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1058 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 807 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1358 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 285 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 27 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 24 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 39 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2150 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 162 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 30 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 48 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 90 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 102 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 148 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 453 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 675 | 0.010 |
Why?
| | Periodicity | 1 | 2000 | 55 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 281 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 44 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2703 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 2 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 22 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 375 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 485 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2266 | 0.010 |
Why?
| | Fever | 1 | 2000 | 301 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1238 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 672 | 0.010 |
Why?
| | Mice | 1 | 2007 | 16579 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|